 |
|
|
|
|
Publications
Bioprocess development for production, purification, and structural characterization of recombinant hCD83ext as a potential therapeutic protein.
Xu Y, Zhang L, Yao W, Yedahalli SS, Brand S, Moo-Young M, Perry Chou C. Protein Expression and Purification, In Press
Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.
Routy J, Boulassel M, Yassine-Diab Y, Nicolette C, Healey D, Jain R, Landry C, Yegorov O, Tcherepanova I, Monesmith T, Finke L and Sekaly R.. Clinical Immunology In press 2010.
Combination immunosuppression involving sCD83 induces adoptively transferable tolerogenic DCs that can prevent cardiac allograft rejection.
Wei Ge, Jacqueline Arp, Dameng Lian, Weihua Liu, Miren L. Baroja, Siobhan Ramcharran, Firas Zahr ElDeen, Elisabeth Zinser, Alex Steinkasserer, Perry Chou, Stephen Brand, Charles Nicolette, Bertha Garcia, Hao Wang, 2009 (Submitted)
Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection.
Tcherepanova I, Harris J, Starr A, Cleveland J, Ketteringham H, David Calderhead, Joe Horvatinovich, Don Healey, Charles A Nicolette. PLoS ONE 3(1): e1489. doi:10.1371/journal.pone.0001489 2008
Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion.
Irina Y Tcherepanova, Melissa D Adams, Xiaorong Feng, Atsushi Hinohara, Joe Horvatinovich, David Calderhead, Don Healey and Charles A Nicolette.
BMC Molecular Biology 2008, 9:90 doi:10.1186/1471-2199-9-90
Priming of a novel subset of CD28: rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells Is IL-12 dependent.
Mark A. DeBenedette, David M. Calderhead, Helen Ketteringham, Alicia H. Gamble, Joe M. Horvatinovich, Irina Y. Tcherepanova, Charles A. Nicolette, and Don G. Healey. The Journal of Immunology, 2008, 181: 5296–5305.
Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent
proinflammatory CTL response.
David M. Calderhead, Mark A. DeBenedette, Helen Ketteringham, Alicia H. Gamble, Joe M. Horvatinovich, Irina Y. Tcherepanova, Charles A. Nicolette, and Don G. Healey. J Immunother 2008; 31:731–741
Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products.
Nicolette C, Healey D., Tcherepanova I., Whelton P., Monesmith t., Coombs L., Finke L., Whiteside T., and Miesowicz F. Vaccine V 25, 2007 pp B48-B60
An improved RNA amplification procedure results in increased yield of autologous RNA transfected dendritic cell-based vaccine.
Jason Harris, Tamara Monesmith, Alicia Ubben, Marcus Norris, Jonathan H Freedman, Irina Tcherepanova. Biochim Biophys Acta. 2005 Jun 20;1724 (1-2):127-36
Dendritic cell subsets generated from CD34(+) hematopoietic progenitors can be transfected with mRNA and induce antigen-specific cytotoxic T cell responses.
Hideki Ueno, Irina Tcherepanova, Olivier Reygrobellet, Erik Laughner, Claire Ventura, A Karolina Palucka, Jacques Banchereau. J Immunol Methods. 2004 Feb 15;285 (2):171-80
PRESENTATIONS
AIDS Vaccine Conference, October 19-22 2009. Paris, France
Immunogenicity of an autologous dendritic cell anti-HIV therapy in HIV-1 infected individuals.
Yassine DB, Coustinos Z, Landry C, Gagnon D, Sauve D, Herbert-Benoit C, Hebert V, Levesque G, Kay P, Bounif N, Boulassel M, Routy J, Jain R, Tcherepanova I, Healey D, Nicolette C and Sekaly R. Poster presentation
Safety and Viral load changes in HIV-1 infected subjects treated with autologous dendritic immune therapy following ART discontinuation.
Routy J, Boulassel M, Loutfy M, Vezina S, Tremblay C, Angel J, Gill J, Baril J, Smaill F, Jain R, Healey D, Tcherepanova I, Nicolette C and Sekaly R. Oral Presentation
5th International IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 19-22 2009 Cape Town, South Africa
Assessing risk of a 12- week antiretroviral therapy discontinuation as a read out of viral control in immune-based therapy (AGS-004-001).
Routy J, Jain R, Boulassel M, Nicolette C, Finke L and Jacobson J. Poster No MOPEB092.
Canadian Association of HIV Researchers, Vancouver, April 23-25th 2009
Safety and feasibility of a multicentre phase 2 trial using autologous dendritic cell (DC) therapy to control viral replication following ART discontinuation (CTN#239).
Routy J, Vezina S, Tremblay C, Baril J, Loutfy M, Gill J, Jain R, Nicolette C, Sekaly R and Boulassel MR for the CTN 239 investigators
A Nursing Perspective of Apheresis Procedures Performed in HIV-Infected Subjects Receiving a Monocytes-Derived Dendritic Cell-Based Immunotherapy.
D Feng , C Goupil , J Mathieu , M. Delisle, S Girard , C Landry , C Gagné , M Swidzinski, MR Boulassel , JP Routy for the CTN-239 Study Investigators
Keystone HIV Immunobiology 2009
The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90.
Irina Tcherepanova, Aijing Starr, Melissa Adams. Brad Lackford, David Calderhead, Don Healey, Mohamed-Rachid Boulassel, Jean-Pierre Routy and Charles Nicolette
10th International Symposium on Dendritic Cells, 2009
Soluble CD83 promotes tolerance induction to minor mismatched skin transplants and allogeneic heart transplants in the mouse.
Elisabeth Zinser, Hao Wang, Stephen Brand, Charles Nicolette, Robert Zhong, William J. Wall and Alexander Steinkasserer
American Society of Transplantation Congress 2009
Soluble CD83 Mediated Suppression of B-cell Activation and Differentiation Prolongs Murine Cardiac Allograft Survival.
Wei Ge, Siobhan I. Ramcharran, Jacqueline Arp, Miren L. Baroja, Zhu Lan, Jifu Jiang, Weihua Liu, Anthony Jevnikar, Stephen Brand, Charles Nicolette, Bertha Garcia, and Hao Wang
Modulation of Dendritic Cells by Soluble CD83 Induces Kidney Allograft Tolerance.
Zhu Lan, Wei Ge, Miren L. Baroja, Jacqueline Arp, Jifu Jiang, Weihua Liu, Stephen Brand, Charles Nicolette, Bertha Garcia, and Hao Wang
Soluble CD83: Its Safety and Efficacy in a Non-Human Primate Kidney Allotransplantation Model.
M L Baroja, Z Lan, J Arp, Weihua LiuG,Strejan, S Brand, C Nicolette, W Wall, B Garcia, D M Rothstein, A M Jevnikar, and H Wang
American Society of Transplantation Congress 2008
The Soluble Extracellular Domain of CD83 is Capable of Generating Regulatory T Cells in Non-Human Primates.
Miren Baroja, Jacqueline Arp, Siobhan Ramcharan, Stephen Brand, Anthony M. Jevnikar, Gill Strejan, William Wall, and Hao Wang
ISCT 14th Annual Meeting 2008
An automated approach for manufacturing personalized dendritic cell immunotherapies.
Monesmith T., Williams l., Martin B., Peel T., Kneen D., Spence S., Grant R., Miesowicz F.
XVII International AIDS Conference 2008
Autologous dendritic cell immunotherapeurtic (Arcellis™ for HIV): tolerability and immunogenicity in HIV-1 infected subjects treated with ART.
Routy, JP, Yassine-Diab, B, Laundry, C, Yegorov, O, Boulassel MR, Benoit-Hebert, C. Antar, R., Tcherepanova, I., Healey, D., Jain R., Finke L, Nicolette, C., Sekaly RP.
Keystone HIV Vaccine 2008
A Phase I safety and feasibility study of autologous dendritic cell therapy in ART treated HIV infected subjects (CAN-HIV-001)
JP Routy, Boulassel NR. Laundry C., Yassine-Diab B., Antar R., Tcherepanova I., Healey D., Miesowicz F., Nicolette C., Finke LH., Sekaly RP.
Post transcriptionally capped HIV RNAs confer higher antigen expression level in DCs.
I. Tcherepanova, A. Starr, A. Raney, D. Calderhead, J. Horvatinovich, D. Healey, C. Nicolette
23rd Annual Meeting of ISBTC 2008
IL-12 as an immunopotency marker for fully autologous dendritic cell immunotherapeutics.
Don Healey, David Calderhead, Alicia Gamble, Joe Horvatinovich, Helen Ketterningham, Irina Tcherepanova, Charles Nicolette and Mark DeBenedette
American Society of Transplantation Congress 2008
The Soluble Extracellular Domain of CD83 is Capable of Generating Regulatory T Cells in Non-Human Primates.
Miren Baroja, Jacqueline Arp, Siobhan Ramcharan, Stephen Brand, Anthony M. Jevnikar, Gill Strejan, William Wall, and Hao Wang
American Society of Transplantation Congress 2007
Soluble CD83 mediated B cell suppression prolongs murine allograft survival
Siobhan Ramcharan, Jacqueline Arp, Miren Baroja Stephen Brand, Gill Strejan, Hao Wang, Anthony M. Jevnikar, and Robert Zhong
Immunosuppressive properties of soluble extracellular domain of CD83 on antigen-presenting cells of cynomologous monkey
Miren Baroja, Jacqueline Arp, Siobhan Ramcharan, Stephen Brand, Anthony M. Jevnikar, Gill Strejan, Hao Wang, William Wall, and Robert Zhong
Targeting a novel immunomodulatory protein by soluble CD83 promote tolerance induction in a mouse cardiac transplantation model
Hao Wang, Wei Ge, Weihua Liu, Dameng Lian, Miren Baroja, Siobhan Ramcharan, Bertha Garcia, Robert Zhong, William Wall
22nd Annual Meeting of ISBTC 2007
PME CD40L DC prime the expansion of CD28+/CD45RA- long lived effector memory CTL having clinical relevance fo dendritic cell based immunotherapies
Don Healey, David Calderhead, Alicia Gamble, Joe Horvatinovich, Helen Ketterningham, Irina Tcherepanova, Charles Nicolette, Mark DeBenedette
Sorafenib but not Sunitinib inhibits human T-cell function in vitro: Implications for combined TKI and Immunotherapy strategies for the treatment of cancer.
Don Healey, David Calderhead, Alicia Gamble, Helen Ketteringham, Robert Figlin, Harry Drabkin, Lothar Finke, Charles Nicolette, Mark DeBenedette
Post-maturation dendritic cells electroporated with CD154 RNA (PME-CD154 DC) prime the expansion of high avidity self-reactive CTL
Mark DeBenedette, David Calderhead, Alicia Gamble, Joe Horvatinovich, Helen Ketteringham, Melissa Adams, Brad Lackford, Irina Tcherepanova, Charles Nicolette and Don Healey
9th International Conference Drug and Gene Based Therapeutics Crete Greece 2006
Novel customized DC based immunotherapy tailored to the infecting patient’s HIV: from conception to clinic.
I. Tcherepanova
13th Annual Meeting CROI 2006 (Denver)
Autologous Nef RNA HIV-1 Electroporated DC enhances the detection of CD8-cpecific proliferative responses.
Oleg Yegorov, Bader Yassine-Diab,Tom Baumgartner, Rachid Boulassel , Jean-Pierre Routy, Don Healey, Irina Tcherepanova, Charles Nicolette and Rafick-Pierre Sekaly
Keystone HIV Vaccine 2006
Optimization of autologous RNA transfected DC therapy product
Irina Tcherepanova, Brad Lackford, Jason Harris, Don Healey, Joe Horvatinovich, Charles Nicolette
9th International Conference on Dendritic Cells 2006
Development of CD4 independent primary CD8 CTL activity in vitro by co-transfection of RNAs encoding antigen and CD40L into pre-matured DC
Don Healey, Mark DeBenedette, Alicia Gamble, Joe Horvatinovich, Helen Ketteringham, Melissa Adams, Brad Lackford, Irina Tcherepanova, Charles Nicolette and David Calderhead
21st Annual Meeting of ISBT 2006
Novel Method of DC Maturation: Intracellular Ligation of CD40 by a truncated CD154 encoded by RNA.
I Tcherepanova., Adams M., Hinohara A., Horvatinovich., J., Healey D., Nicolette C., J. Immunotherapy, Abstracts of 21st annual meeting of ISBT V 29 n6 2006 p670.
Keystone Symposium 2007: “Immunological Intervention in Human Disease”
Development of CD4 independent primary CD8 CTL activity in vitro by co-transfection of RNAs encoding antigen and CD40L into prematured DC
David Calderhead, Mark DeBenedette, Alicia Gamble, Joe Horvatinovich, Helen Ketteringham, Melissa Adams, Brad Lackford, Irina Tcherepanova, Charles Nicolette and Don Healey
Keystone HIV Vaccine 2005
Autologous RNA transfected dendritic cell based anti HIV vaccine.
I. Tcherepanova., Harris J., Lackford B., Calderhead D.
AIDS Vaccine 2005 (Montreal)
Autologous HIV electroporated DC enhances the detection of CD8 specific proliferative responses.
O. Yegorov, Yassine Diab B., Chambenoit O., Gangon B., Boulassel R., Routy JP., Heley D., Harris J., Tcherepanova I., Nicolette C., Sekaly RP.
AIDS Vaccine 2005 (Montreal)
A novel strain-independent anti HIV vaccine targets autologous virus and its quasispecies.
Tcherepanova I., Harris J., Lackford B., Yassine Diab., B., Yegorov O., Sekaly RP., Nicolette C.
Keystone Symposium 2005: “Dendritic Cells at the Center of Innate and Adaptive Immunity: Eradication of Pathogens and Cancer and Control of Immunopathology”
Development of CD4+ independent CD8+ CTL activity in vitro by transfection of CD154 (CD40 ligand) mRNA into dendritic cells
David Calderhead, Alicia Hedgepeth, Helen Ketteringham, Joe Horvatinovich, Charles Nicolette and Don Healey
Keystone 2004
Flu-MP RNA-transfected subsets of CD34-HPCs derived DCs induce potent recall immune responses.
Hideki Ueno, Irina Tcherepanova, Olivier Reygrobellet, Claire Ventura, A. Karolina Palucka and Jacques Banchereau. Baylor Institute for Immunology Research Dallas, TX and Merix Bioscience, Inc
|
|
 |
|
